Buprenorphine is used both as an analgesic and in opioid dependence treatment. Its pharmacodynamic properties that make it suitable for opioid substitution therapy include:

• A Full mu-opioid receptor agonism with high intrinsic efficacy causing maximal analgesia
• B Pure kappa-opioid receptor agonism with no mu receptor activity
• C Competitive antagonism at mu receptors without intrinsic analgesic activity
• D Partial mu-opioid receptor agonism with very high affinity (displaces full agonists) and a ceiling effect on respiratory depression ✓

Explanation

Buprenorphine is a partial agonist at mu-opioid receptors with exceptionally high receptor affinity (Kd in picomolar range) — meaning it competitively displaces full agonists like heroin and morphine. As a partial agonist, its dose-response curve is bell-shaped, reaching a ceiling effect for both analgesia and respiratory depression. This ceiling on respiratory depression is the safety advantage for maintenance treatment. Its high affinity also means it is resistant to displacement by full agonists (precipitating withdrawal in opioid-dependent patients if given during active use), and naloxone is often co-formulated to deter intravenous misuse.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.